CEO comments on InDex Pharmaceuticals interim report - Q3 2022
Index Pharmaceuticals released their interim report for the third quarter of 2022 this week and we spoke with acting CEO Johan Giléus, who had the following comments.
Period July – September 2022
All comparative amounts in brackets refer to the outcome during the corresponding period 2021.
1. Cash & Cash equivalents
The company confirms they currently have sufficient funds for the first induction study (Induction study 1) and the applicable part of the Maintenance study.
2. Conclude study
Patient recruitment for the phase III study CONCLUDE with cobitolimod is underway and a number of clinics have been very active in enrolling patients. However, the study has had a slower start-up than expected with several underlying reasons. Nevertheless, acting CEO Johan Giléus confirms that InDex Pharmaceuticals has launched and are launching measures with the aim to be able to meet the communicated timeplan.
3. JAK inhibitors – the previous treatment of UC
Pfizer faced some serious commercial headwinds last year with their third line product Xeljanz, a JAK-inhibitor to treat UC, after FDA announced additional safety warnings for JAK-inhibitors. Now EMA’s safety committee has recommended new measures to limit the use of JAK-inhibitors. This is positive news for InDex Pharmaceuticals and their lead drug candidate for the treatment of left sided UC, Cobitolimod, with its clean safety profile.
Disclaimer: HC Andersen Capital receives payment from Index Pharmaceuticals for a Digital IR/Corporate Visibility agreement. /Claus Thestrup kl. 08.10 AM d. 11/24/2022
Login required
This content is only available for logged in users
InDex Pharmaceuticals Holding
InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
Read more on company page